Drug-Drug Interaction (DDI™) Effectiveness and Clinical Awareness Randomized Controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 330
- 试验地点
- 2
- 主要终点
- Drug-Drug Interaction (DDI) diagnosis
研究概览
简要总结
The DECART study will determine if primary care physicians, including internists and family physicians, are able to identify and address drug-drug interactions among simulated patients and whether those physicians, when given access to Aegis Drug-Drug Interaction test results, improve patient management, take steps to reduce DDI risk, and optimize unnecessary resource utilization.
详细描述
The DECART study is a pre-post, two round, randomized controlled study of a nationally representative sample of 330 primary care physicians randomly assigned to a control or one of two intervention arms. Once eligibility is determined and providers are enrolled in the study, they will be asked to complete a questionnaire describing their practice and professional background. They will then care for a total of 6 CPV® simulated patients. The simulated patients will be adults aged 30-75 and present with various clinical conditions and potential drug interactions. The design and intervention consists of two rounds with an intervention among two thirds of the participants.
- Round 1 (Baseline Assessment): Providers in both the control and intervention groups will care for 3 CPV simulated patients using their standard practice approach, to evaluate their awareness of DDI interactions and associated variability in caring for patients at risk for DDIs.
- Intervention/DD! Education: Approximately 3 weeks after CPV Round 1 is complete, the intervention arms will receive Aegis test education materials, consisting of: 1) on-demand, online video on the Aegis DDI test, 2) example test results, 3) example case study, 4) clinical care reference guide, and 5) test overview.
- Round 2 (Post-Educational Intervention Assessment): Approximately 3 weeks after the intervention, all providers in the control and intervention arms will receive another 3 simulated patients to care for to determine if their awareness has changed and if their practice has improved. In the post--educational assessment, one-half of intervention participants will have access to Aegis DDI test results for their patients to help guide their decision making. The other half will have the option of receiving test results if ordered. Control physicians will continue to their standard practice approach.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Single (Care Provider)
盲法说明
Single-blind masking
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Provide consent to participate in the study
- •Board-certified physician currently practicing in the following areas:
- •Internal medicine
- •Family medicine
- •Have practiced as a board-certified physician in internal or family medicine for greater than 2 but less than 30 years.
- •Have not used Aegis DDI
- •English-speaking
- •Community/ non-academic based practice setting
- •40 patients under care weekly
- •15% of their patient panel on opioid pain medications
- •Access to the internet
排除标准
- •Provide consent to participate in the study
- •Board-certified physician currently practicing in the following areas:
- •Internal medicine
- •Family medicine
- •Have practiced as a board-certified physician in internal or family medicine for greater than 2 but less than 30 years.
- •Have not used Aegis DDI
- •English-speaking
- •Community/ non-academic based practice setting
- •40 patients under care weekly
- •15% of their patient panel on opioid pain medications
- •Access to the internet
研究组 & 干预措施
Standard Practice
Not receiving any intervention/educational materials on drug-drug interaction testing
Compulsory DDI Testing
Receiving educational materials on drug-drug interaction testing and a sample test report when caring for patient cases.
干预措施: DDI Test Report (Diagnostic Test)
Optional DDI Testing
Receiving educational materials on drug-drug interaction testing and given a sample test report if ordered when caring for patient cases.
干预措施: DDI Test Report (Diagnostic Test)
结局指标
主要结局
Drug-Drug Interaction (DDI) diagnosis
时间窗: 3 months
Difference in difference between the control and the intervention group in their identification and effective treatment of DDls.
次要结局
- Quality of care(3 months)
- DDI adoption(3 months)
- Resource utilization(3 months)